Titlebook: Disease-modifying Therapy in Vasculitides; Cees G. M. Kallenberg,Jan W. Cohen Tervaert Book 2001 Birkh?user Verlag 2001 Internal medicine.

hexagon

書(shū)目名稱Disease-modifying Therapy in Vasculitides影響因子(影響力)




書(shū)目名稱Disease-modifying Therapy in Vasculitides影響因子(影響力)學(xué)科排名




書(shū)目名稱Disease-modifying Therapy in Vasculitides網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Disease-modifying Therapy in Vasculitides網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Disease-modifying Therapy in Vasculitides被引頻次




書(shū)目名稱Disease-modifying Therapy in Vasculitides被引頻次學(xué)科排名




書(shū)目名稱Disease-modifying Therapy in Vasculitides年度引用




書(shū)目名稱Disease-modifying Therapy in Vasculitides年度引用學(xué)科排名




書(shū)目名稱Disease-modifying Therapy in Vasculitides讀者反饋




書(shū)目名稱Disease-modifying Therapy in Vasculitides讀者反饋學(xué)科排名

可轉(zhuǎn)變

1422-7746 dicine, connective tissue disease and clinical immunology, they present new concepts in classificiation, diagnosis and pathophysiology of the vasculitides. Evidence from experimental and clinical trials is reviewed, as well as the outlook for further research.978-3-0348-9485-2978-3-0348-8235-4Series ISSN 1422-7746 Series E-ISSN 2296-4525

uveitis

Philip Michalk,Bertram Meimbresse rheumatoid arthritis (RA) and Crohn’s disease has revolutionized the treatment of these diseases [.-.]. The extrapolation and rigorous testing of cytokine modulation strategies in the vasculitides have enormous potential to improve therapies for this group of disorders.

SEED

色情

NOCT

Intravenous immunoglobulin as immuno-modifying treatment,s of autoimmunity. There has been widespread clinical use of IgIV as a second line treatment for many autoimmune diseases with relatively few randomised studies demonstrating its clinical effectiveness.

NOCT

conflate

天空

似少年

,Interferon-α for the treatment of virus-related systemic vasculitides,itides with IFNα. Two types of IFNα are commonly prescribed, IFNα 2a and IFNα 2b. They differ by one amino acid but no difference in efficacy has been shown. The other types of IFN, that is, IFNβ and IFNγ, are not prescribed for virus-associated vasculitides.